İlerlemiş/Metastatik Hormon Pozitif HER2 Negatif Meme Kanserinde CDK4/6 İnhibitörü Sonrası Tedavi
Özet
Bu bölüm, hormon reseptörü pozitif ve HER2 negatif metastatik meme kanserinde CDK4/6 inhibitörü sonrası tedavi yaklaşımlarını kapsamlı biçimde ele almaktadır. CDK4/6 inhibitörlerine direnç geliştiğinde uygulanabilecek endokrin bazlı ve hedefe yönelik tedavi seçenekleri klinik verilerle birlikte değerlendirilmektedir. ESR1, PIK3CA, AKT1 ve PTEN gibi genetik alterasyonların tedavi seçimindeki rolü, güncel faz III çalışmalar üzerinden özetlenmektedir. Ayrıca ileri basamak tedavi alternatifleri, antikor-ilaç konjugatları ve PARP inhibitörleri gibi yeni jenerasyon ajanlar ışığında tartışılmaktadır. Bölüm, kişiselleştirilmiş tedavi yaklaşımlarının önemini vurgulayarak klinik pratikte karar süreçlerine yön göstermektedir.
Referanslar
Fribbens C, O'Leary B, Kilburn L, ve ark. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961.
Chandarlapaty S, Chen D, He W, ve ark. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310.
Chia S, Gradishar W, Mauriac L, ve ark. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664.
Di Leo A, Jerusalem G, Petruzelka L, ve ark. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106:djt337.
Kornblum N, Zhao F, Manola J, ve ark. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36:1556.
Schmid P, Zaiss M, Harper-Wynne C, ve ark. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1556.
Vasseur A, Cabel L, Hego C, ve ark. Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene. 2024;43:1214.
Kalinsky K, Bianchini G, Hamilton E, ve ark. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43:1101.
Kalinsky K, Accordino MK, Chiuzan C, ve ark. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41:4004.
Llombart-Cussac A, Harper-Wynne C, Perelló A, ve ark. Second-line endocrine therapy with or without palbociclib rechallenge in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: PALMIRA trial. J Clin Oncol. 2025;43:2084.
Jhaveri K, Eli LD, Wildiers H, ve ark. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023;34:885.
Baselga J, Campone M, Piccart M, ve ark. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520.
Piccart M, Hortobagyi GN, Campone M, ve ark. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25:2357.
Bachelot T, Bourgier C, Cropet C, ve ark. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30:2718.
ORSERDU (elacestrant) tablets, for oral use. United States Prescribing Information. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf (Accessed on January 30, 2023).
Bidard FC, Kaklamani VG, Neven P, ve ark. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246.
Bardia A, Bidard FC, Neven P, ve ark. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy. Sunulan yer: San Antonio Breast Cancer Symposium (SABCS); 2022.
Bidard FC, Hardy-Bessard AC, Dalenc F, ve ark. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1367.
Bidard FC, Mayer EL, Park YH, ve ark. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025.
Goetz MP, Bagegni NA, Batist G, ve ark. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023;34:1141.
Damodaran S, O'Sullivan CC, Elkhanany A, ve ark. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023;34:1131.
Jhaveri KL, Neven P, Casalnuovo ML, ve ark. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189.
Campone M, De Laurentiis M, Jhaveri K, ve ark. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61.
TRUQAP (capivasertib) tablets, for oral use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf (Accessed on December 12, 2023).
Turner NC, Oliveira M, Howell SJ, ve ark. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058.
Oliveira M, Rugo HS, Howell SJ, ve ark. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2024;25:1231.
Howell SJ, Casbard A, Carucci M, ve ark. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23:851.
André F, Ciruelos E, Rubovszky G, ve ark. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929.
André F, Ciruelos EM, Juric D, ve ark. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021;32:208.
Rugo HS, Lerebours F, Ciruelos E, ve ark. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25:e629.
Rugo HS, Lacouture ME, Goncalves MD, ve ark. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022;61:156.
TRUQAP (capivasertib) tablets, for oral use. US Prescribing Information. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf (Accessed on December 12, 2023).
Cochrane DR, Bernales S, Jacobsen BM, ve ark. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.
Dickler MN, Barry WT, Cirrincione CT, ve ark. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016;34:2602.
Martín M, Loibl S, von Minckwitz G, ve ark. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015;33:1045.
Krop IE, Mayer IA, Ganju V, ve ark. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811.
Baselga J, Dent SF, Cortes J, ve ark. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J Clin Oncol. 2018;36S(suppl; abstr 1006).
Dent S, Cortés J, Im YH, ve ark. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32:197.
Gradishar WJ, Moran MS, Abraham J, ve ark. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:691.
Rugo H, Bardia A, Marme F, ve ark. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(suppl; abstr LBA1001).
Abemaciclib tablets. Unites States Prescribing Information. US National Library of Medicine. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf (Accessed on March 20, 2018).
Dickler MN, Tolaney SM, Rugo HS, ve ark. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23:5218.
Abrams J, Aisner J, Cirrincione C, ve ark. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999;17:64.
Willemse PH, van der Ploeg E, Sleijfer DT, ve ark. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer. 1990;26:337.
Kornblith AB, Hollis DR, Zuckerman E, ve ark. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol. 1993;11:2081.
Mattsson W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat. 1983;3:231.
Ellis MJ, Gao F, Dehdashti F, ve ark. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302:774.
Ingle JN, Ahmann DL, Green SJ, ve ark. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304:16.
Goldenberg IS. Results of studies of the cooperative breast cancer group--1961-63. Cancer Chemother Rep. 1964;41(Suppl):1.
Coombes RC, Dearnaley D, Humphreys J, ve ark. Danazol treatment of advanced breast cancer. Cancer Treat Rep. 1980;64:1073.
Manni A, Arafah BM, Pearson OH. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer. 1981;48:2507.
Schifeling DJ, Jackson DV, Zekan PJ, Muss HB. Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol. 1992;15:233.
Fan L, Liedke PE, Isakoff SJ, ve ark. Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review. Clin Breast Cancer. 2014;14:e41.
Chavarri-Guerra Y, Higgins MJ, Szymonifka J, ve ark. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. Br J Cancer. 2014;111:2046.
Fasching PA, Yadav S, Hu C, et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39:1619.
Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377:523.
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379:753.
